PTEN and melanoma: More generally, stimulation of adenylate cyclase activity by forskolin promotes tumor growth in the BrafCA/Pten−/− melanoma mouse model, whereas its pharmacological inhibition by SQ22536 leads to a decrease in tumor growth in a MAPK pathway-independent manner [124,125].